Clover Biopharmaceuticals (2197 HK)

Analysis

Health Care • China

Clover Biopharmaceuticals is a global commercial-stage biotechnology company focused on developing innovative vaccines and biologic therapeutic candidates. The company designs, tests, and manufactures biologic products using its protein engineering and cell-culture technology. Its pipeline includes vaccines for seasonal influenza, COVID-19, Respiratory Syncytial Virus (RSV), and pneumococcal conjugated vaccines (PCV), as well as therapeutic candidates for infectious diseases, cancer, and autoimmune diseases. Headquartered in Chengdu, China, the company was founded in 2007.

Refresh

Exchange Announcement • 30 Sep 2026 17:15

2026 Interim Report

Exchange Announcement • 07 Sep 2026 06:11

Voluntary Announcement Clover Announces Positive Australia Phase 2 Clinical Data For Rsv + Hmpv + Piv3 Respiratory Combination Vaccine Candidates In Older Adults

Exchange Announcement • 26 Aug 2026 06:07

Interim Results Announcement For The Six Months Ended June 30, 2026

Exchange Announcement • 13 Aug 2026 16:30

Date Of Board Meeting

Exchange Announcement • 20 Jul 2026 07:03

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

2026 Interim Report

Voluntary Announcement Clover Announces Positive Australia Phase 2 Clinical Data For Rsv + Hmpv + Piv3 Respiratory Combination Vaccine Candidates In Older Adults

Interim Results Announcement For The Six Months Ended June 30, 2026

Date Of Board Meeting

Positive Profit Alert